Investment accounts
Adult accounts
Child accounts
Choosing Fidelity
Choosing Fidelity
Why invest with us Current offers Fees and charges Open an account Transfer investments
Financial advice & support
Fidelity’s Services
Fidelity’s Services
Financial advice Retirement Wealth Management Investor Centre (London) Bereavement
Guidance and tools
Guidance and tools
Choosing investments Choosing accounts ISA calculator Retirement calculators
Share dealing
Choose your shares
Tools and information
Tools and information
Share prices and markets Chart and compare shares Stock market news Shareholder perks IPOs and placings
Pensions & retirement
Pensions, tax & tools
Saving for retirement
Approaching / In retirement
Approaching / In retirement
Speak to a specialist Creating a retirement plan Taking tax-free cash Pension drawdown Annuities Investing in retirement Investment Pathways
C4X Discovery shares soar on $11m COPD payment from AstraZeneca
(Sharecast News) - C4X Discovery, the AIM-listed drug discovery company, has received a "milestone payment" of $11m from biopharma giant AstraZeneca as part of the progress of its NRF2 Activator programme, causing shares to jump by nearly a half on Wednesday. Back in November 2022, C4XD signed an exclusive global licensing agreement with AstraZeneca for the development and commercialisation of NRF2 Activator programme, an oral therapy for the treatment of inflammatory and respiratory diseases with a lead focus on chronic obstructive pulmonary disease (COPD).
C4XD initially received $2m upfront and is potentially entitled to receive up to $400m in preclinical, clinical development and commercial milestones, and to tiered mid-single digit royalties on future sales.
"This significant preclinical milestone payment marks the progress AstraZeneca has made in driving the NRF2 Activator programme forward," said C4XD chief executive Clive Dix.
"This is a great start to our year and we are confident of seeing further progress across our entire portfolio in 2024."
C4XD reported in December that full-year revenues for the 12 months to 31 July totalled just £1.7m, down from £2.7m the year before, as it recorded a pre-tax loss of £11.1m.
The stock was up 43% at 12.5p by 0826 GMT, hitting an earlier high of 14.5p, compared with Tuesday's close of 8.74p.
Analyst Sean Conroy from Shore Capital said the payment is an "important value inflection which should reinvigorate sentiment in the share".
"Moreover, this serves as timely reminder that C4XD has licensing deals in place with some of the leading developers for its programmes. These agreements serve as strong validation of C4XD's prowess in drug discovery and demonstrate its ability to distil value from assets early in the development process," Conroy said.
Share this article
Related Sharecast Articles
Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.
Award-winning online share dealing
Search, compare and select from thousands of shares.
Expert insights into investing your money
Our team of experts explore the world of share dealing.
Policies and important information
Accessibility | Conflicts of interest statement | Consumer Duty Target Market | Consumer Duty Value Assessment Statement | Cookie policy | Diversity and Inclusion | Doing Business with Fidelity | Fidelity gender pay report | Investing in Fidelity funds | Legal information | Modern slavery | Mutual respect policy | Privacy statement | Remuneration policy | Security | Statutory and Regulatory disclosures | Whistleblowing policy
Please remember that past performance is not necessarily a guide to future performance, the performance of investments is not guaranteed, and the value of your investments can go down as well as up, so you may get back less than you invest. When investments have particular tax features, these will depend on your personal circumstances and tax rules may change in the future. This website does not contain any personal recommendations for a particular course of action, service or product. You should regularly review your investment objectives and choices and, if you are unsure whether an investment is suitable for you, you should contact an authorised financial adviser. Before opening an account, please read the ‘Doing Business with Fidelity’ document which incorporates our client terms. Prior to investing into a fund, please read the relevant key information document which contains important information about the fund.
This website is issued by Financial Administration Services Limited, which is authorised and regulated by the Financial Conduct Authority (FCA) (FCA Register number 122169) and registered in England and Wales under company number 1629709 whose registered address is Beech Gate, Millfield Lane, Lower Kingswood, Tadworth, Surrey, KT20 6RP.